The two faces of the IL-15- Janus Kinase-Stat system: implications for the immunotherapy of autoimmune diseases and cancer

ce06ae6f15ee6e1234fe9b483fc4fb67 National Cancer Institute {"start": "2017-11-29T20:00:00", "end": "2017-11-29T21:00:00"}

Thomas A. Waldmann, M.D.
Waldmann, Thomas A., M.D. NIH Distinguished Investigator

Dr. Walmann will present the annual William Paul lecture. Dr. Waldmann defined the IL-2 receptor alpha and beta subunits using the daclizumab antibody he discovered, an antibody that is approved by the FDA. He co-discovered IL-15 and performed the first in-human clinical trial with this agent in patients with malignancy. Furthermore, Waldmann defined molecular abnormalities of the common gamma cytokine, Jak/Stat signaling pathway in HTLV-1 associated adult T-cell lymphoma and translated this discovery with a trial of a Jak inhibitor in patients with this disorder.

https://videocast.nih.gov/watch=26622 https://ccr.cancer.gov/Lymphoid-Malignancies-Branch/thomas-a-waldmann